中文摘要：

目的：检测EGR4在卵巢肿瘤组织中的表达,分析EGR4与上皮性卵巢癌临床病理因素间的关系,并探讨EGR4与上皮性卵巢癌耐药性的相关性。方法：收集2006年11月至2012年11月于西京医院就诊的有完整病史和临床资料的原发性上皮性卵巢癌患者86例。应用免疫组织化学染色的方法检测86例上皮性卵巢癌、17例良性上皮性卵巢肿瘤和14例交界性上皮性卵巢肿瘤组织中EGR4的表达情况。分析EGR4表达与患者临床病理因素及化疗耐药性之间的关系。结果：上皮性卵巢癌组织中EGR4蛋白表达较良性卵巢肿瘤和交界性卵巢肿瘤组织中表达明显增高,三组之间有统计学意义（P〈0.05）;上皮性卵巢癌组织中EGR4高表达与患者手术-病理分期、病理类型、腹水及肿瘤细胞减灭术有关（P〈0.05）,而与患者年龄、组织分化程度、淋巴结转移及肿瘤大小等指标无关（P〉0.05）;上皮性卵巢癌组织中EGR4表达与患者化疗耐药性无关（P〉0.05）。结论：EGR4在上皮性卵巢癌组织中呈高表达,且EGR4高表达与患者手术-病理分期、病理类型、腹水及肿瘤细胞减灭术有关,提示EGR4可能参与上皮性卵巢癌的发生发展等过程;上皮性卵巢癌组织中EGR4表达与患者化疗耐药性无关。

英文摘要：

Objective： To detect the expression of EGR4 in ovarian tumor tissue,and analyze the relationship between EGR4 and clinical factors of ovarian epithelial carcinoma,explore the correlation between EGR4 and drug resistance of ovarian epithelial carcinoma. Methods： Collect 86 cases of primary ovarian epithelial cancer patients with complete clinical data diagnosed from November 2006 to November 2012 in Xijing Hospital. Immunofluorescence assay was used to detect the expression of EGR4 protein in ovarian cancer,benign ovarian tumors and borderline ovarian tumors. The relationships between the expression of EGR4 and the clinical index,drug resistance were analyzed. Results： The expression of EGR4 was higher in ovarian epithelial carcinoma than that in ovarian epithelial benign tumor and ovarian epithelial borderline tumor tissues（ P〈0.05）. The expression of EGR4 in ovarian epithelial carcinoma was correlated with FIGO staging,pathological type,ascites and cytoreductive surgery（ P〈0.05）,but not correlated with histological differentiation,lymph node metastasis and tumor size（ P〉0.05）. The expression of EGR4 in ovarian epithelial carcinoma was not correlated with platinum resistance in patients（ P〉0.05）. Conclusion： The high expression of EGR4 in ovarian epithelial carcinoma was correlated with FIGO staging,pathological type,ascites and cytoreductive surgery,which indicates EGR4 can participate in development and progress of ovarian cancer.